Apellis Pharmaceuticals (NASDAQ:APLS) Earns “Neutral” Rating from Cantor Fitzgerald

Apellis Pharmaceuticals (NASDAQ:APLS)‘s stock had its “neutral” rating restated by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports.

Several other equities research analysts have also recently issued reports on APLS. William Blair cut shares of Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Raymond James Financial cut Apellis Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday, April 1st. Roth Mkm lowered Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $41.00 price objective (up from $37.00) on shares of Apellis Pharmaceuticals in a research report on Wednesday, April 1st. Finally, Mizuho increased their target price on Apellis Pharmaceuticals from $20.00 to $41.00 and gave the company a “neutral” rating in a report on Thursday, April 2nd. Three equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $35.72.

Apellis Pharmaceuticals Price Performance

APLS opened at $41.03 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 3.16 and a current ratio of 3.63. The stock has a market capitalization of $5.25 billion, a P/E ratio of 40.23 and a beta of -0.24. The company’s 50-day simple moving average is $32.35 and its two-hundred day simple moving average is $26.05. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $41.14.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.44. Apellis Pharmaceuticals had a net margin of 12.06% and a return on equity of 39.71%. The firm had revenue of $268.30 million for the quarter, compared to the consensus estimate of $208.91 million. As a group, analysts predict that Apellis Pharmaceuticals will post -1.14 EPS for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Kryger Capital LLC bought a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at $44,253,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Apellis Pharmaceuticals during the first quarter valued at $48,360,000. Renaissance Technologies LLC lifted its position in Apellis Pharmaceuticals by 47.8% during the first quarter. Renaissance Technologies LLC now owns 935,958 shares of the company’s stock valued at $37,654,000 after purchasing an additional 302,900 shares in the last quarter. Gabelli Funds LLC bought a new stake in Apellis Pharmaceuticals during the first quarter valued at about $12,922,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in Apellis Pharmaceuticals in the first quarter worth about $8,070,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.